nodes	percent_of_prediction	percent_of_DWPC	metapath
Loperamide—POMC—osteoporosis	0.433	1	CbGaD
Loperamide—Cloperastine—Raloxifene—osteoporosis	0.17	1	CrCrCtD
Loperamide—CYP2B6—Raloxifene—osteoporosis	0.0245	0.107	CbGbCtD
Loperamide—CYP2B6—Ethinyl Estradiol—osteoporosis	0.0236	0.103	CbGbCtD
Loperamide—CYP2B6—Cholecalciferol—osteoporosis	0.0189	0.0824	CbGbCtD
Loperamide—CYP2C8—Raloxifene—osteoporosis	0.0185	0.0808	CbGbCtD
Loperamide—CYP2C8—Ethinyl Estradiol—osteoporosis	0.0179	0.0781	CbGbCtD
Loperamide—CYP2C8—Cholecalciferol—osteoporosis	0.0143	0.0624	CbGbCtD
Loperamide—ABCB1—Ethinyl Estradiol—osteoporosis	0.0121	0.0528	CbGbCtD
Loperamide—CYP2C8—Estradiol—osteoporosis	0.0115	0.0503	CbGbCtD
Loperamide—CYP3A4—Estropipate—osteoporosis	0.0113	0.0491	CbGbCtD
Loperamide—CYP3A4—Calcitriol—osteoporosis	0.0113	0.0491	CbGbCtD
Loperamide—CYP2D6—Cholecalciferol—osteoporosis	0.00913	0.0398	CbGbCtD
Loperamide—CYP3A4—Ergocalciferol—osteoporosis	0.00901	0.0393	CbGbCtD
Loperamide—ABCB1—Conjugated Estrogens—osteoporosis	0.00889	0.0388	CbGbCtD
Loperamide—ABCB1—Estradiol—osteoporosis	0.00781	0.034	CbGbCtD
Loperamide—CYP3A4—Raloxifene—osteoporosis	0.00752	0.0328	CbGbCtD
Loperamide—CYP3A4—Ethinyl Estradiol—osteoporosis	0.00726	0.0317	CbGbCtD
Loperamide—CYP3A4—Cholecalciferol—osteoporosis	0.0058	0.0253	CbGbCtD
Loperamide—CYP3A4—Conjugated Estrogens—osteoporosis	0.00533	0.0232	CbGbCtD
Loperamide—CYP3A4—Estradiol—osteoporosis	0.00468	0.0204	CbGbCtD
Loperamide—POMC—vertebral column—osteoporosis	0.00176	0.766	CbGeAlD
Loperamide—Toremifene—ESR1—osteoporosis	0.0003	0.228	CrCbGaD
Loperamide—Dry mouth—Calcitriol—osteoporosis	0.000259	0.00315	CcSEcCtD
Loperamide—Immune system disorder—Pamidronate—osteoporosis	0.000258	0.00314	CcSEcCtD
Loperamide—Flatulence—Risedronate—osteoporosis	0.000258	0.00314	CcSEcCtD
Loperamide—Urinary tract disorder—Zoledronate—osteoporosis	0.000258	0.00314	CcSEcCtD
Loperamide—Nervous system disorder—Raloxifene—osteoporosis	0.000257	0.00312	CcSEcCtD
Loperamide—Urethral disorder—Zoledronate—osteoporosis	0.000256	0.00311	CcSEcCtD
Loperamide—Gastrointestinal pain—Etidronic acid—osteoporosis	0.000256	0.00311	CcSEcCtD
Loperamide—Skin disorder—Raloxifene—osteoporosis	0.000254	0.00309	CcSEcCtD
Loperamide—Nervous system disorder—Ibandronate—osteoporosis	0.000254	0.00309	CcSEcCtD
Loperamide—Anaphylactic shock—Calcitriol—osteoporosis	0.000254	0.00309	CcSEcCtD
Loperamide—Abdominal distension—Estradiol—osteoporosis	0.000253	0.00308	CcSEcCtD
Loperamide—Skin disorder—Ibandronate—osteoporosis	0.000252	0.00306	CcSEcCtD
Loperamide—Nausea—Ergocalciferol—osteoporosis	0.00025	0.00304	CcSEcCtD
Loperamide—Urticaria—Etidronic acid—osteoporosis	0.000248	0.00302	CcSEcCtD
Loperamide—Abdominal pain—Etidronic acid—osteoporosis	0.000247	0.00301	CcSEcCtD
Loperamide—Skin disorder—Calcitriol—osteoporosis	0.000247	0.003	CcSEcCtD
Loperamide—Angioedema—Ethinyl Estradiol—osteoporosis	0.000245	0.00298	CcSEcCtD
Loperamide—Somnolence—Estropipate—osteoporosis	0.00024	0.00292	CcSEcCtD
Loperamide—Angioedema—Risedronate—osteoporosis	0.000239	0.00291	CcSEcCtD
Loperamide—Dyspepsia—Estropipate—osteoporosis	0.000238	0.0029	CcSEcCtD
Loperamide—Erythema multiforme—Conjugated Estrogens—osteoporosis	0.000238	0.00289	CcSEcCtD
Loperamide—Immune system disorder—Zoledronate—osteoporosis	0.000236	0.00287	CcSEcCtD
Loperamide—Dyspepsia—Alendronate—osteoporosis	0.000234	0.00285	CcSEcCtD
Loperamide—Gastrointestinal disorder—Estropipate—osteoporosis	0.000233	0.00284	CcSEcCtD
Loperamide—Fatigue—Estropipate—osteoporosis	0.000233	0.00284	CcSEcCtD
Loperamide—Constipation—Estropipate—osteoporosis	0.000231	0.00281	CcSEcCtD
Loperamide—Dyspepsia—Raloxifene—osteoporosis	0.000231	0.0028	CcSEcCtD
Loperamide—Hypersensitivity—Etidronic acid—osteoporosis	0.00023	0.0028	CcSEcCtD
Loperamide—Loss of consciousness—Risedronate—osteoporosis	0.00023	0.0028	CcSEcCtD
Loperamide—Dyspepsia—Ibandronate—osteoporosis	0.000228	0.00278	CcSEcCtD
Loperamide—Constipation—Alendronate—osteoporosis	0.000228	0.00277	CcSEcCtD
Loperamide—Angioedema—Pamidronate—osteoporosis	0.000227	0.00277	CcSEcCtD
Loperamide—Immune system disorder—Conjugated Estrogens—osteoporosis	0.000227	0.00276	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Ethinyl Estradiol—osteoporosis	0.000227	0.00276	CcSEcCtD
Loperamide—Gastrointestinal disorder—Raloxifene—osteoporosis	0.000226	0.00275	CcSEcCtD
Loperamide—Discomfort—Ethinyl Estradiol—osteoporosis	0.000226	0.00275	CcSEcCtD
Loperamide—Somnolence—Calcitriol—osteoporosis	0.000226	0.00274	CcSEcCtD
Loperamide—Gastrointestinal disorder—Ibandronate—osteoporosis	0.000224	0.00272	CcSEcCtD
Loperamide—Fatigue—Ibandronate—osteoporosis	0.000224	0.00272	CcSEcCtD
Loperamide—Constipation—Ibandronate—osteoporosis	0.000222	0.0027	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Risedronate—osteoporosis	0.000221	0.00269	CcSEcCtD
Loperamide—Pruritus—Etidronic acid—osteoporosis	0.000221	0.00269	CcSEcCtD
Loperamide—Gastrointestinal pain—Estropipate—osteoporosis	0.000221	0.00269	CcSEcCtD
Loperamide—Levomethadyl Acetate—CYP19A1—osteoporosis	0.00022	0.168	CrCbGaD
Loperamide—Clotrimazole—CYP19A1—osteoporosis	0.00022	0.168	CrCbGaD
Loperamide—Loss of consciousness—Pamidronate—osteoporosis	0.000219	0.00266	CcSEcCtD
Loperamide—Dry mouth—Risedronate—osteoporosis	0.000218	0.00265	CcSEcCtD
Loperamide—Gastrointestinal pain—Alendronate—osteoporosis	0.000218	0.00265	CcSEcCtD
Loperamide—Constipation—Calcitriol—osteoporosis	0.000217	0.00264	CcSEcCtD
Loperamide—Flatulence—Conjugated Estrogens—osteoporosis	0.000216	0.00262	CcSEcCtD
Loperamide—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.000215	0.00261	CcSEcCtD
Loperamide—Urticaria—Estropipate—osteoporosis	0.000215	0.00261	CcSEcCtD
Loperamide—Gastrointestinal pain—Raloxifene—osteoporosis	0.000214	0.00261	CcSEcCtD
Loperamide—Diarrhoea—Etidronic acid—osteoporosis	0.000214	0.0026	CcSEcCtD
Loperamide—Abdominal pain—Estropipate—osteoporosis	0.000214	0.0026	CcSEcCtD
Loperamide—Skin disorder—Ethinyl Estradiol—osteoporosis	0.000213	0.00259	CcSEcCtD
Loperamide—Gastrointestinal pain—Ibandronate—osteoporosis	0.000212	0.00258	CcSEcCtD
Loperamide—Urticaria—Alendronate—osteoporosis	0.000212	0.00257	CcSEcCtD
Loperamide—Abdominal pain—Alendronate—osteoporosis	0.00021	0.00256	CcSEcCtD
Loperamide—Nervous system disorder—Risedronate—osteoporosis	0.00021	0.00255	CcSEcCtD
Loperamide—Discomfort—Pamidronate—osteoporosis	0.000209	0.00255	CcSEcCtD
Loperamide—Angioedema—Zoledronate—osteoporosis	0.000208	0.00253	CcSEcCtD
Loperamide—Skin disorder—Risedronate—osteoporosis	0.000208	0.00252	CcSEcCtD
Loperamide—Gastrointestinal pain—Calcitriol—osteoporosis	0.000208	0.00252	CcSEcCtD
Loperamide—Abdominal pain—Raloxifene—osteoporosis	0.000207	0.00252	CcSEcCtD
Loperamide—Urticaria—Ibandronate—osteoporosis	0.000206	0.00251	CcSEcCtD
Loperamide—Abdominal pain—Ibandronate—osteoporosis	0.000205	0.00249	CcSEcCtD
Loperamide—Anaphylactic shock—Pamidronate—osteoporosis	0.000203	0.00247	CcSEcCtD
Loperamide—Urticaria—Calcitriol—osteoporosis	0.000202	0.00245	CcSEcCtD
Loperamide—Abdominal pain—Calcitriol—osteoporosis	0.000201	0.00244	CcSEcCtD
Loperamide—Angioedema—Conjugated Estrogens—osteoporosis	0.0002	0.00243	CcSEcCtD
Loperamide—Loss of consciousness—Zoledronate—osteoporosis	0.0002	0.00243	CcSEcCtD
Loperamide—Hypersensitivity—Estropipate—osteoporosis	0.000199	0.00242	CcSEcCtD
Loperamide—Nervous system disorder—Pamidronate—osteoporosis	0.000199	0.00242	CcSEcCtD
Loperamide—Urinary tract disorder—Estradiol—osteoporosis	0.000199	0.00242	CcSEcCtD
Loperamide—Vomiting—Etidronic acid—osteoporosis	0.000199	0.00242	CcSEcCtD
Loperamide—Urethral disorder—Estradiol—osteoporosis	0.000197	0.0024	CcSEcCtD
Loperamide—Rash—Etidronic acid—osteoporosis	0.000197	0.0024	CcSEcCtD
Loperamide—Dermatitis—Etidronic acid—osteoporosis	0.000197	0.00239	CcSEcCtD
Loperamide—Hypersensitivity—Alendronate—osteoporosis	0.000196	0.00239	CcSEcCtD
Loperamide—Headache—Etidronic acid—osteoporosis	0.000196	0.00238	CcSEcCtD
Loperamide—Tamoxifen—ESR2—osteoporosis	0.000194	0.148	CrCbGaD
Loperamide—Asthenia—Estropipate—osteoporosis	0.000194	0.00236	CcSEcCtD
Loperamide—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.000192	0.00234	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000192	0.00234	CcSEcCtD
Loperamide—Pruritus—Estropipate—osteoporosis	0.000191	0.00233	CcSEcCtD
Loperamide—Discomfort—Zoledronate—osteoporosis	0.000191	0.00233	CcSEcCtD
Loperamide—Asthenia—Alendronate—osteoporosis	0.000191	0.00232	CcSEcCtD
Loperamide—Hypersensitivity—Ibandronate—osteoporosis	0.000191	0.00232	CcSEcCtD
Loperamide—Erythema multiforme—Estradiol—osteoporosis	0.00019	0.00231	CcSEcCtD
Loperamide—Dry mouth—Zoledronate—osteoporosis	0.000189	0.0023	CcSEcCtD
Loperamide—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000189	0.0023	CcSEcCtD
Loperamide—Fatigue—Ethinyl Estradiol—osteoporosis	0.000189	0.0023	CcSEcCtD
Loperamide—Pruritus—Alendronate—osteoporosis	0.000188	0.00229	CcSEcCtD
Loperamide—Dyspepsia—Risedronate—osteoporosis	0.000188	0.00229	CcSEcCtD
Loperamide—Constipation—Ethinyl Estradiol—osteoporosis	0.000187	0.00228	CcSEcCtD
Loperamide—Hypersensitivity—Calcitriol—osteoporosis	0.000187	0.00227	CcSEcCtD
Loperamide—Asthenia—Ibandronate—osteoporosis	0.000186	0.00226	CcSEcCtD
Loperamide—Nausea—Etidronic acid—osteoporosis	0.000186	0.00226	CcSEcCtD
Loperamide—Anaphylactic shock—Zoledronate—osteoporosis	0.000186	0.00226	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000185	0.00225	CcSEcCtD
Loperamide—Diarrhoea—Estropipate—osteoporosis	0.000185	0.00225	CcSEcCtD
Loperamide—Gastrointestinal disorder—Risedronate—osteoporosis	0.000184	0.00224	CcSEcCtD
Loperamide—Fatigue—Risedronate—osteoporosis	0.000184	0.00224	CcSEcCtD
Loperamide—Pruritus—Ibandronate—osteoporosis	0.000183	0.00223	CcSEcCtD
Loperamide—Constipation—Risedronate—osteoporosis	0.000183	0.00222	CcSEcCtD
Loperamide—Diarrhoea—Alendronate—osteoporosis	0.000182	0.00222	CcSEcCtD
Loperamide—Asthenia—Calcitriol—osteoporosis	0.000182	0.00222	CcSEcCtD
Loperamide—Nervous system disorder—Zoledronate—osteoporosis	0.000182	0.00221	CcSEcCtD
Loperamide—Immune system disorder—Estradiol—osteoporosis	0.000182	0.00221	CcSEcCtD
Loperamide—Somnolence—Pamidronate—osteoporosis	0.000181	0.0022	CcSEcCtD
Loperamide—Skin disorder—Zoledronate—osteoporosis	0.00018	0.00219	CcSEcCtD
Loperamide—Pruritus—Calcitriol—osteoporosis	0.00018	0.00218	CcSEcCtD
Loperamide—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000179	0.00218	CcSEcCtD
Loperamide—Diarrhoea—Raloxifene—osteoporosis	0.000179	0.00218	CcSEcCtD
Loperamide—Dyspepsia—Pamidronate—osteoporosis	0.000179	0.00218	CcSEcCtD
Loperamide—Dizziness—Estropipate—osteoporosis	0.000179	0.00218	CcSEcCtD
Loperamide—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.000179	0.00217	CcSEcCtD
Loperamide—Diarrhoea—Ibandronate—osteoporosis	0.000177	0.00216	CcSEcCtD
Loperamide—Dizziness—Alendronate—osteoporosis	0.000176	0.00214	CcSEcCtD
Loperamide—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000175	0.00213	CcSEcCtD
Loperamide—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000175	0.00213	CcSEcCtD
Loperamide—Fatigue—Pamidronate—osteoporosis	0.000175	0.00213	CcSEcCtD
Loperamide—Gastrointestinal pain—Risedronate—osteoporosis	0.000175	0.00213	CcSEcCtD
Loperamide—Urticaria—Ethinyl Estradiol—osteoporosis	0.000174	0.00212	CcSEcCtD
Loperamide—Constipation—Pamidronate—osteoporosis	0.000174	0.00211	CcSEcCtD
Loperamide—Diarrhoea—Calcitriol—osteoporosis	0.000174	0.00211	CcSEcCtD
Loperamide—Skin disorder—Conjugated Estrogens—osteoporosis	0.000174	0.00211	CcSEcCtD
Loperamide—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000173	0.00211	CcSEcCtD
Loperamide—Dizziness—Raloxifene—osteoporosis	0.000173	0.00211	CcSEcCtD
Loperamide—Flatulence—Estradiol—osteoporosis	0.000173	0.0021	CcSEcCtD
Loperamide—Vomiting—Estropipate—osteoporosis	0.000172	0.00209	CcSEcCtD
Loperamide—Dizziness—Ibandronate—osteoporosis	0.000171	0.00209	CcSEcCtD
Loperamide—Rash—Estropipate—osteoporosis	0.00017	0.00207	CcSEcCtD
Loperamide—Dermatitis—Estropipate—osteoporosis	0.00017	0.00207	CcSEcCtD
Loperamide—Urticaria—Risedronate—osteoporosis	0.00017	0.00206	CcSEcCtD
Loperamide—Headache—Estropipate—osteoporosis	0.000169	0.00206	CcSEcCtD
Loperamide—Vomiting—Alendronate—osteoporosis	0.000169	0.00206	CcSEcCtD
Loperamide—Abdominal pain—Risedronate—osteoporosis	0.000169	0.00205	CcSEcCtD
Loperamide—Rash—Alendronate—osteoporosis	0.000168	0.00204	CcSEcCtD
Loperamide—Dermatitis—Alendronate—osteoporosis	0.000168	0.00204	CcSEcCtD
Loperamide—Headache—Alendronate—osteoporosis	0.000167	0.00203	CcSEcCtD
Loperamide—Vomiting—Raloxifene—osteoporosis	0.000167	0.00203	CcSEcCtD
Loperamide—Gastrointestinal pain—Pamidronate—osteoporosis	0.000166	0.00202	CcSEcCtD
Loperamide—Rash—Raloxifene—osteoporosis	0.000165	0.00201	CcSEcCtD
Loperamide—Dermatitis—Raloxifene—osteoporosis	0.000165	0.00201	CcSEcCtD
Loperamide—Somnolence—Zoledronate—osteoporosis	0.000165	0.00201	CcSEcCtD
Loperamide—Vomiting—Ibandronate—osteoporosis	0.000165	0.00201	CcSEcCtD
Loperamide—Headache—Raloxifene—osteoporosis	0.000164	0.002	CcSEcCtD
Loperamide—Rash—Ibandronate—osteoporosis	0.000163	0.00199	CcSEcCtD
Loperamide—Dermatitis—Ibandronate—osteoporosis	0.000163	0.00199	CcSEcCtD
Loperamide—Dyspepsia—Zoledronate—osteoporosis	0.000163	0.00199	CcSEcCtD
Loperamide—Headache—Ibandronate—osteoporosis	0.000162	0.00198	CcSEcCtD
Loperamide—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000161	0.00196	CcSEcCtD
Loperamide—Vomiting—Calcitriol—osteoporosis	0.000161	0.00196	CcSEcCtD
Loperamide—Nausea—Estropipate—osteoporosis	0.000161	0.00195	CcSEcCtD
Loperamide—Abdominal pain—Pamidronate—osteoporosis	0.000161	0.00195	CcSEcCtD
Loperamide—Gastrointestinal disorder—Zoledronate—osteoporosis	0.00016	0.00195	CcSEcCtD
Loperamide—Angioedema—Estradiol—osteoporosis	0.00016	0.00195	CcSEcCtD
Loperamide—Rash—Calcitriol—osteoporosis	0.00016	0.00195	CcSEcCtD
Loperamide—Fatigue—Zoledronate—osteoporosis	0.00016	0.00195	CcSEcCtD
Loperamide—Dermatitis—Calcitriol—osteoporosis	0.00016	0.00194	CcSEcCtD
Loperamide—Headache—Calcitriol—osteoporosis	0.000159	0.00193	CcSEcCtD
Loperamide—Somnolence—Conjugated Estrogens—osteoporosis	0.000159	0.00193	CcSEcCtD
Loperamide—Constipation—Zoledronate—osteoporosis	0.000159	0.00193	CcSEcCtD
Loperamide—Nausea—Alendronate—osteoporosis	0.000158	0.00192	CcSEcCtD
Loperamide—Hypersensitivity—Risedronate—osteoporosis	0.000157	0.00192	CcSEcCtD
Loperamide—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000157	0.00191	CcSEcCtD
Loperamide—Asthenia—Ethinyl Estradiol—osteoporosis	0.000157	0.00191	CcSEcCtD
Loperamide—Nausea—Raloxifene—osteoporosis	0.000156	0.00189	CcSEcCtD
Loperamide—Pruritus—Ethinyl Estradiol—osteoporosis	0.000155	0.00189	CcSEcCtD
Loperamide—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000154	0.00188	CcSEcCtD
Loperamide—Fatigue—Conjugated Estrogens—osteoporosis	0.000154	0.00187	CcSEcCtD
Loperamide—Nausea—Ibandronate—osteoporosis	0.000154	0.00187	CcSEcCtD
Loperamide—Loss of consciousness—Estradiol—osteoporosis	0.000154	0.00187	CcSEcCtD
Loperamide—Asthenia—Risedronate—osteoporosis	0.000153	0.00186	CcSEcCtD
Loperamide—Constipation—Conjugated Estrogens—osteoporosis	0.000153	0.00186	CcSEcCtD
Loperamide—Gastrointestinal pain—Zoledronate—osteoporosis	0.000152	0.00185	CcSEcCtD
Loperamide—Pruritus—Risedronate—osteoporosis	0.000151	0.00184	CcSEcCtD
Loperamide—Nausea—Calcitriol—osteoporosis	0.000151	0.00183	CcSEcCtD
Loperamide—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.00015	0.00182	CcSEcCtD
Loperamide—Hypersensitivity—Pamidronate—osteoporosis	0.00015	0.00182	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000148	0.0018	CcSEcCtD
Loperamide—Urticaria—Zoledronate—osteoporosis	0.000147	0.00179	CcSEcCtD
Loperamide—Discomfort—Estradiol—osteoporosis	0.000147	0.00179	CcSEcCtD
Loperamide—Abdominal pain—Zoledronate—osteoporosis	0.000147	0.00178	CcSEcCtD
Loperamide—Diarrhoea—Risedronate—osteoporosis	0.000146	0.00178	CcSEcCtD
Loperamide—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000146	0.00178	CcSEcCtD
Loperamide—Dry mouth—Estradiol—osteoporosis	0.000146	0.00177	CcSEcCtD
Loperamide—Asthenia—Pamidronate—osteoporosis	0.000146	0.00177	CcSEcCtD
Loperamide—Dizziness—Ethinyl Estradiol—osteoporosis	0.000145	0.00176	CcSEcCtD
Loperamide—Pruritus—Pamidronate—osteoporosis	0.000144	0.00175	CcSEcCtD
Loperamide—Anaphylactic shock—Estradiol—osteoporosis	0.000143	0.00174	CcSEcCtD
Loperamide—Urticaria—Conjugated Estrogens—osteoporosis	0.000142	0.00173	CcSEcCtD
Loperamide—Dizziness—Risedronate—osteoporosis	0.000141	0.00172	CcSEcCtD
Loperamide—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000141	0.00172	CcSEcCtD
Loperamide—Nervous system disorder—Estradiol—osteoporosis	0.00014	0.00171	CcSEcCtD
Loperamide—Vomiting—Ethinyl Estradiol—osteoporosis	0.000139	0.0017	CcSEcCtD
Loperamide—Diarrhoea—Pamidronate—osteoporosis	0.000139	0.00169	CcSEcCtD
Loperamide—Skin disorder—Estradiol—osteoporosis	0.000139	0.00169	CcSEcCtD
Loperamide—Rash—Ethinyl Estradiol—osteoporosis	0.000138	0.00168	CcSEcCtD
Loperamide—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000138	0.00168	CcSEcCtD
Loperamide—Headache—Ethinyl Estradiol—osteoporosis	0.000137	0.00167	CcSEcCtD
Loperamide—Hypersensitivity—Zoledronate—osteoporosis	0.000137	0.00166	CcSEcCtD
Loperamide—Vomiting—Risedronate—osteoporosis	0.000136	0.00165	CcSEcCtD
Loperamide—Rash—Risedronate—osteoporosis	0.000135	0.00164	CcSEcCtD
Loperamide—Dermatitis—Risedronate—osteoporosis	0.000135	0.00164	CcSEcCtD
Loperamide—Dizziness—Pamidronate—osteoporosis	0.000134	0.00163	CcSEcCtD
Loperamide—Headache—Risedronate—osteoporosis	0.000134	0.00163	CcSEcCtD
Loperamide—Asthenia—Zoledronate—osteoporosis	0.000133	0.00162	CcSEcCtD
Loperamide—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000132	0.0016	CcSEcCtD
Loperamide—Pruritus—Zoledronate—osteoporosis	0.000131	0.0016	CcSEcCtD
Loperamide—Nausea—Ethinyl Estradiol—osteoporosis	0.00013	0.00158	CcSEcCtD
Loperamide—Tamoxifen—CYP19A1—osteoporosis	0.00013	0.0991	CrCbGaD
Loperamide—Vomiting—Pamidronate—osteoporosis	0.000129	0.00157	CcSEcCtD
Loperamide—Methadone—CYP19A1—osteoporosis	0.000129	0.0982	CrCbGaD
Loperamide—Asthenia—Conjugated Estrogens—osteoporosis	0.000128	0.00156	CcSEcCtD
Loperamide—Rash—Pamidronate—osteoporosis	0.000128	0.00156	CcSEcCtD
Loperamide—Dermatitis—Pamidronate—osteoporosis	0.000128	0.00156	CcSEcCtD
Loperamide—Headache—Pamidronate—osteoporosis	0.000127	0.00155	CcSEcCtD
Loperamide—Somnolence—Estradiol—osteoporosis	0.000127	0.00155	CcSEcCtD
Loperamide—Diarrhoea—Zoledronate—osteoporosis	0.000127	0.00154	CcSEcCtD
Loperamide—Nausea—Risedronate—osteoporosis	0.000127	0.00154	CcSEcCtD
Loperamide—Pruritus—Conjugated Estrogens—osteoporosis	0.000126	0.00154	CcSEcCtD
Loperamide—Dyspepsia—Estradiol—osteoporosis	0.000126	0.00153	CcSEcCtD
Loperamide—Gastrointestinal disorder—Estradiol—osteoporosis	0.000123	0.0015	CcSEcCtD
Loperamide—Fatigue—Estradiol—osteoporosis	0.000123	0.0015	CcSEcCtD
Loperamide—Dizziness—Zoledronate—osteoporosis	0.000123	0.00149	CcSEcCtD
Loperamide—Constipation—Estradiol—osteoporosis	0.000122	0.00149	CcSEcCtD
Loperamide—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000122	0.00149	CcSEcCtD
Loperamide—Nausea—Pamidronate—osteoporosis	0.000121	0.00147	CcSEcCtD
Loperamide—Tamoxifen—ESR1—osteoporosis	0.00012	0.0912	CrCbGaD
Loperamide—Dizziness—Conjugated Estrogens—osteoporosis	0.000118	0.00144	CcSEcCtD
Loperamide—Vomiting—Zoledronate—osteoporosis	0.000118	0.00144	CcSEcCtD
Loperamide—Rash—Zoledronate—osteoporosis	0.000117	0.00142	CcSEcCtD
Loperamide—Gastrointestinal pain—Estradiol—osteoporosis	0.000117	0.00142	CcSEcCtD
Loperamide—Dermatitis—Zoledronate—osteoporosis	0.000117	0.00142	CcSEcCtD
Loperamide—Headache—Zoledronate—osteoporosis	0.000116	0.00141	CcSEcCtD
Loperamide—Vomiting—Conjugated Estrogens—osteoporosis	0.000114	0.00138	CcSEcCtD
Loperamide—Urticaria—Estradiol—osteoporosis	0.000114	0.00138	CcSEcCtD
Loperamide—Abdominal pain—Estradiol—osteoporosis	0.000113	0.00138	CcSEcCtD
Loperamide—Rash—Conjugated Estrogens—osteoporosis	0.000113	0.00137	CcSEcCtD
Loperamide—Dermatitis—Conjugated Estrogens—osteoporosis	0.000113	0.00137	CcSEcCtD
Loperamide—Headache—Conjugated Estrogens—osteoporosis	0.000112	0.00136	CcSEcCtD
Loperamide—Nausea—Zoledronate—osteoporosis	0.00011	0.00134	CcSEcCtD
Loperamide—Nausea—Conjugated Estrogens—osteoporosis	0.000106	0.00129	CcSEcCtD
Loperamide—Hypersensitivity—Estradiol—osteoporosis	0.000105	0.00128	CcSEcCtD
Loperamide—Asthenia—Estradiol—osteoporosis	0.000103	0.00125	CcSEcCtD
Loperamide—Pruritus—Estradiol—osteoporosis	0.000101	0.00123	CcSEcCtD
Loperamide—CALM3—uterus—osteoporosis	0.000101	0.044	CbGeAlD
Loperamide—Diarrhoea—Estradiol—osteoporosis	9.78e-05	0.00119	CcSEcCtD
Loperamide—Dizziness—Estradiol—osteoporosis	9.45e-05	0.00115	CcSEcCtD
Loperamide—Vomiting—Estradiol—osteoporosis	9.09e-05	0.00111	CcSEcCtD
Loperamide—Rash—Estradiol—osteoporosis	9.01e-05	0.0011	CcSEcCtD
Loperamide—Dermatitis—Estradiol—osteoporosis	9.01e-05	0.0011	CcSEcCtD
Loperamide—Headache—Estradiol—osteoporosis	8.96e-05	0.00109	CcSEcCtD
Loperamide—CALM3—bone marrow—osteoporosis	8.57e-05	0.0373	CbGeAlD
Loperamide—Nausea—Estradiol—osteoporosis	8.49e-05	0.00103	CcSEcCtD
Loperamide—CALM2—uterus—osteoporosis	7.93e-05	0.0345	CbGeAlD
Loperamide—CALM1—uterus—osteoporosis	7.89e-05	0.0344	CbGeAlD
Loperamide—CALM2—bone marrow—osteoporosis	6.73e-05	0.0293	CbGeAlD
Loperamide—CALM1—bone marrow—osteoporosis	6.7e-05	0.0292	CbGeAlD
Loperamide—ABCB1—uterus—osteoporosis	3.15e-05	0.0137	CbGeAlD
Loperamide—ABCB1—bone marrow—osteoporosis	2.67e-05	0.0116	CbGeAlD
Loperamide—CALM2—Signaling Pathways—CNR2—osteoporosis	6.67e-06	8.24e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—PSMA2—osteoporosis	6.62e-06	8.18e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—PSMA5—osteoporosis	6.62e-06	8.18e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—TPI1—osteoporosis	6.61e-06	8.16e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—P4HB—osteoporosis	6.59e-06	8.14e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—NFATC1—osteoporosis	6.56e-06	8.1e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—NFATC1—osteoporosis	6.56e-06	8.1e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—ESR1—osteoporosis	6.54e-06	8.08e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—DKK1—osteoporosis	6.51e-06	8.04e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—DKK1—osteoporosis	6.51e-06	8.04e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—ENO1—osteoporosis	6.5e-06	8.03e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—ENO1—osteoporosis	6.5e-06	8.03e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—WNT1—osteoporosis	6.48e-06	8e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by Wnt—MYC—osteoporosis	6.48e-06	8e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by Wnt—MYC—osteoporosis	6.48e-06	8e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—KL—osteoporosis	6.47e-06	7.99e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—KL—osteoporosis	6.47e-06	7.99e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—GAPDH—osteoporosis	6.47e-06	7.99e-05	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—IL6—osteoporosis	6.45e-06	7.96e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PSMA5—osteoporosis	6.41e-06	7.91e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PSMA2—osteoporosis	6.41e-06	7.91e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PSMA5—osteoporosis	6.41e-06	7.91e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PSMA2—osteoporosis	6.41e-06	7.91e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism of lipids and lipoproteins—POMC—osteoporosis	6.31e-06	7.79e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—FGA—osteoporosis	6.31e-06	7.79e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—RAP1A—osteoporosis	6.3e-06	7.78e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—WNT1—osteoporosis	6.27e-06	7.74e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—WNT1—osteoporosis	6.27e-06	7.74e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—ADCY5—osteoporosis	6.21e-06	7.67e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—P4HB—osteoporosis	6.21e-06	7.67e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—IRS2—osteoporosis	6.14e-06	7.58e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—CA2—osteoporosis	6.13e-06	7.57e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—OXCT1—osteoporosis	6.13e-06	7.57e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—IRS1—osteoporosis	6.11e-06	7.55e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—FGA—osteoporosis	6.1e-06	7.53e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—FGA—osteoporosis	6.1e-06	7.53e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—GAPDH—osteoporosis	6.1e-06	7.53e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—ADCY5—osteoporosis	6.01e-06	7.42e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—ADCY5—osteoporosis	6.01e-06	7.42e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—LEP—osteoporosis	6.01e-06	7.42e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—MGLL—osteoporosis	5.97e-06	7.38e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—RAP1A—osteoporosis	5.94e-06	7.33e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—ADCY5—osteoporosis	5.93e-06	7.32e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—POMC—osteoporosis	5.89e-06	7.27e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PTHLH—osteoporosis	5.86e-06	7.24e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—BMP2—osteoporosis	5.86e-06	7.24e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—ENO1—osteoporosis	5.85e-06	7.22e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PSMA5—osteoporosis	5.76e-06	7.11e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PSMA2—osteoporosis	5.76e-06	7.11e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—IL6R—osteoporosis	5.74e-06	7.09e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—SPP1—osteoporosis	5.74e-06	7.09e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—FGB—osteoporosis	5.74e-06	7.08e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—ESR1—osteoporosis	5.74e-06	7.08e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—AGER—osteoporosis	5.7e-06	7.04e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—ADCY5—osteoporosis	5.68e-06	7.01e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PTHLH—osteoporosis	5.67e-06	7e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PTHLH—osteoporosis	5.67e-06	7e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—BMP2—osteoporosis	5.67e-06	7e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—BMP2—osteoporosis	5.67e-06	7e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—IGF1—osteoporosis	5.66e-06	6.99e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—FGB—osteoporosis	5.55e-06	6.85e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—FGB—osteoporosis	5.55e-06	6.85e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PSMA5—osteoporosis	5.54e-06	6.84e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PSMA2—osteoporosis	5.54e-06	6.84e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—CYP19A1—osteoporosis	5.52e-06	6.82e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—AGER—osteoporosis	5.51e-06	6.81e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—AGER—osteoporosis	5.51e-06	6.81e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—ADCY5—osteoporosis	5.49e-06	6.78e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—ADCY5—osteoporosis	5.49e-06	6.78e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by NGF—IL6—osteoporosis	5.46e-06	6.75e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—CYP19A1—osteoporosis	5.37e-06	6.64e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—IRS1—osteoporosis	5.36e-06	6.62e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PSMA2—osteoporosis	5.36e-06	6.62e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PSMA2—osteoporosis	5.36e-06	6.62e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PSMA5—osteoporosis	5.36e-06	6.62e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PSMA5—osteoporosis	5.36e-06	6.62e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by NGF—IL6—osteoporosis	5.29e-06	6.53e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by NGF—IL6—osteoporosis	5.29e-06	6.53e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—ADCY5—osteoporosis	5.24e-06	6.47e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—CYP19A1—osteoporosis	5.2e-06	6.42e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—CYP19A1—osteoporosis	5.2e-06	6.42e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—IRS2—osteoporosis	5.19e-06	6.41e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—POMC—osteoporosis	5.16e-06	6.37e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CALCA—osteoporosis	5.16e-06	6.37e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—ENO1—osteoporosis	5.09e-06	6.29e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—IDH2—osteoporosis	5.08e-06	6.27e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—LEP—osteoporosis	5.08e-06	6.27e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—ADCY5—osteoporosis	5.07e-06	6.26e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—ADCY5—osteoporosis	5.07e-06	6.26e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—IL6R—osteoporosis	5.04e-06	6.22e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PSMA2—osteoporosis	5.02e-06	6.2e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PSMA5—osteoporosis	5.02e-06	6.2e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CALCA—osteoporosis	4.99e-06	6.17e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CALCA—osteoporosis	4.99e-06	6.17e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—IRS2—osteoporosis	4.97e-06	6.13e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—IGF1—osteoporosis	4.97e-06	6.13e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—ESR1—osteoporosis	4.85e-06	5.99e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—MTHFR—osteoporosis	4.82e-06	5.95e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—IRS2—osteoporosis	4.81e-06	5.93e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—IRS2—osteoporosis	4.81e-06	5.93e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—ENO1—osteoporosis	4.8e-06	5.93e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—CYP27A1—osteoporosis	4.78e-06	5.9e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PSMA5—osteoporosis	4.73e-06	5.84e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PSMA2—osteoporosis	4.73e-06	5.84e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—KL—osteoporosis	4.69e-06	5.79e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—CYP19A1—osteoporosis	4.67e-06	5.77e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—MTHFR—osteoporosis	4.66e-06	5.76e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—MTHFR—osteoporosis	4.66e-06	5.76e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—ACP5—osteoporosis	4.65e-06	5.74e-05	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—TGFB1—osteoporosis	4.59e-06	5.67e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—IRS2—osteoporosis	4.59e-06	5.66e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—POMC—osteoporosis	4.57e-06	5.64e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—KL—osteoporosis	4.53e-06	5.6e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—KL—osteoporosis	4.53e-06	5.6e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—IRS1—osteoporosis	4.53e-06	5.59e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—ADCY5—osteoporosis	4.51e-06	5.57e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—GPX1—osteoporosis	4.5e-06	5.55e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—IL6R—osteoporosis	4.46e-06	5.51e-05	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—TGFB1—osteoporosis	4.44e-06	5.49e-05	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—TGFB1—osteoporosis	4.44e-06	5.49e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—IRS2—osteoporosis	4.44e-06	5.48e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—IRS2—osteoporosis	4.44e-06	5.48e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—POMC—osteoporosis	4.42e-06	5.46e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—POMC—osteoporosis	4.42e-06	5.46e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—ADCY5—osteoporosis	4.39e-06	5.42e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—GPX1—osteoporosis	4.38e-06	5.4e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—POMC—osteoporosis	4.36e-06	5.39e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—IRS1—osteoporosis	4.34e-06	5.36e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—IL6—osteoporosis	4.33e-06	5.35e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—TPI1—osteoporosis	4.32e-06	5.33e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—IL6R—osteoporosis	4.31e-06	5.33e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—IL6R—osteoporosis	4.31e-06	5.33e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—IL6R—osteoporosis	4.26e-06	5.25e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—ADCY5—osteoporosis	4.25e-06	5.24e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—ADCY5—osteoporosis	4.25e-06	5.24e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—GPX1—osteoporosis	4.23e-06	5.23e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—GPX1—osteoporosis	4.23e-06	5.23e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—IGF1—osteoporosis	4.2e-06	5.18e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—IRS1—osteoporosis	4.2e-06	5.18e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—IRS1—osteoporosis	4.2e-06	5.18e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—MTHFR—osteoporosis	4.15e-06	5.12e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—IL6R—osteoporosis	4.07e-06	5.03e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—CYP19A1—osteoporosis	4.07e-06	5.03e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—P4HB—osteoporosis	4.06e-06	5.01e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—MTHFR—osteoporosis	4.04e-06	4.99e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—IRS1—osteoporosis	4e-06	4.94e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—GAPDH—osteoporosis	3.99e-06	4.92e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—IL6R—osteoporosis	3.94e-06	4.87e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—IL6R—osteoporosis	3.94e-06	4.87e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—MTHFR—osteoporosis	3.91e-06	4.82e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—MTHFR—osteoporosis	3.91e-06	4.82e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—RAP1A—osteoporosis	3.88e-06	4.79e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—IRS1—osteoporosis	3.87e-06	4.78e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—IRS1—osteoporosis	3.87e-06	4.78e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—CYP19A1—osteoporosis	3.84e-06	4.74e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—ADCY5—osteoporosis	3.82e-06	4.72e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—GPX1—osteoporosis	3.81e-06	4.7e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—IL6—osteoporosis	3.8e-06	4.69e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—IL6R—osteoporosis	3.76e-06	4.64e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—ADCY5—osteoporosis	3.67e-06	4.53e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—IL6R—osteoporosis	3.64e-06	4.49e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—IL6R—osteoporosis	3.64e-06	4.49e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—SPP1—osteoporosis	3.55e-06	4.39e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—ADCY5—osteoporosis	3.55e-06	4.39e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—ADCY5—osteoporosis	3.55e-06	4.39e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—MTHFR—osteoporosis	3.51e-06	4.34e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—SPP1—osteoporosis	3.44e-06	4.24e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—SPP1—osteoporosis	3.44e-06	4.24e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—MYC—osteoporosis	3.4e-06	4.2e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—TGFB1—osteoporosis	3.39e-06	4.19e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—ADCY5—osteoporosis	3.33e-06	4.11e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—POMC—osteoporosis	3.32e-06	4.1e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—GPX1—osteoporosis	3.32e-06	4.09e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—POMC—osteoporosis	3.23e-06	3.99e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IRS2—osteoporosis	3.21e-06	3.97e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—IL6—osteoporosis	3.21e-06	3.96e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—LEP—osteoporosis	3.14e-06	3.88e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—ENO1—osteoporosis	3.14e-06	3.88e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—ADCY5—osteoporosis	3.14e-06	3.87e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—GPX1—osteoporosis	3.12e-06	3.86e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—POMC—osteoporosis	3.12e-06	3.86e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—POMC—osteoporosis	3.12e-06	3.86e-05	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—IL6—osteoporosis	3.12e-06	3.85e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IRS2—osteoporosis	3.11e-06	3.84e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IRS2—osteoporosis	3.11e-06	3.84e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—IL1B—osteoporosis	3.1e-06	3.83e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PSMA2—osteoporosis	3.09e-06	3.82e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PSMA5—osteoporosis	3.09e-06	3.82e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—MTHFR—osteoporosis	3.06e-06	3.78e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—LEP—osteoporosis	3.04e-06	3.75e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—LEP—osteoporosis	3.04e-06	3.75e-05	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—IL6—osteoporosis	3.01e-06	3.72e-05	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—IL6—osteoporosis	3.01e-06	3.72e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—ESR1—osteoporosis	3e-06	3.71e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—IL1B—osteoporosis	3e-06	3.7e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—IL1B—osteoporosis	3e-06	3.7e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—MYC—osteoporosis	2.98e-06	3.68e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—TGFB1—osteoporosis	2.98e-06	3.68e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—ESR1—osteoporosis	2.9e-06	3.58e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—ESR1—osteoporosis	2.9e-06	3.58e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—MTHFR—osteoporosis	2.88e-06	3.56e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—POMC—osteoporosis	2.81e-06	3.47e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IRS1—osteoporosis	2.8e-06	3.46e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IRS1—osteoporosis	2.71e-06	3.35e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IRS1—osteoporosis	2.71e-06	3.35e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—POMC—osteoporosis	2.7e-06	3.33e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IL6R—osteoporosis	2.63e-06	3.25e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—POMC—osteoporosis	2.61e-06	3.23e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—POMC—osteoporosis	2.61e-06	3.23e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IGF1—osteoporosis	2.6e-06	3.21e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—IL6—osteoporosis	2.56e-06	3.16e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IL6R—osteoporosis	2.55e-06	3.15e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IL6R—osteoporosis	2.55e-06	3.15e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—MYC—osteoporosis	2.52e-06	3.11e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—TGFB1—osteoporosis	2.52e-06	3.11e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IGF1—osteoporosis	2.51e-06	3.1e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IGF1—osteoporosis	2.51e-06	3.1e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—CYP19A1—osteoporosis	2.51e-06	3.1e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—POMC—osteoporosis	2.45e-06	3.02e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—POMC—osteoporosis	2.31e-06	2.85e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—IL6—osteoporosis	2.24e-06	2.77e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—MYC—osteoporosis	2.23e-06	2.75e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—TGFB1—osteoporosis	2.22e-06	2.75e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—MYC—osteoporosis	2.16e-06	2.66e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—MYC—osteoporosis	2.16e-06	2.66e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—TGFB1—osteoporosis	2.15e-06	2.66e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—TGFB1—osteoporosis	2.15e-06	2.66e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—ADCY5—osteoporosis	2.05e-06	2.53e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—GPX1—osteoporosis	2.04e-06	2.52e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—IL6—osteoporosis	1.99e-06	2.45e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—IL6—osteoporosis	1.92e-06	2.37e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—IL6—osteoporosis	1.92e-06	2.37e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—IL6—osteoporosis	1.9e-06	2.34e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—MTHFR—osteoporosis	1.89e-06	2.33e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—IL6—osteoporosis	1.81e-06	2.24e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—IL6—osteoporosis	1.76e-06	2.17e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—IL6—osteoporosis	1.76e-06	2.17e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—IL6—osteoporosis	1.68e-06	2.07e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—IL6—osteoporosis	1.62e-06	2e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—IL6—osteoporosis	1.62e-06	2e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MYC—osteoporosis	1.56e-06	1.93e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—TGFB1—osteoporosis	1.56e-06	1.92e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MYC—osteoporosis	1.51e-06	1.86e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MYC—osteoporosis	1.51e-06	1.86e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—POMC—osteoporosis	1.51e-06	1.86e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—TGFB1—osteoporosis	1.51e-06	1.86e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—TGFB1—osteoporosis	1.51e-06	1.86e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IL6—osteoporosis	1.17e-06	1.45e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IL6—osteoporosis	1.14e-06	1.4e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IL6—osteoporosis	1.14e-06	1.4e-05	CbGpPWpGaD
